Molecular structure of Tirabrutinib, CAS Number: 1351636-18-4
Tirabrutinib (CAS 1351636-18-4)
Alternate Names:
ONO-4059; GS-4059
CAS Number:
1351636-18-4
Molecular Weight:
454.48
Molecular Formula:
C25H22N6O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Tirabrutinib (CAS 1351636-18-4) References
- Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. | Kozaki, R., et al. 2023. PLoS One. 18: e0282166. PMID: 36897912
- Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines. | Dostálová, H., et al. 2023. Invest New Drugs. 41: 210-219. PMID: 36913160
- Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives. | Kaburaki, T. and Taoka, K. 2023. Jpn J Ophthalmol. 67: 363-381. PMID: 37209195
- BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib. | Jackson, RA., et al. 2023. Blood Adv. 7: 3378-3381. PMID: 37257190
- Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib. | Lin, DY. and Andreotti, AH. 2023. PLoS One. 18: e0290872. PMID: 37651403
- Bruton's tyrosine kinase is a possible therapeutic target in microscopic polyangiitis. | Nakade, I., et al. 2023. Arthritis Res Ther. 25: 215. PMID: 37932784
- Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia. | Joseph, RE., et al. 2023. bioRxiv.. PMID: 38187560
- The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS. | Xia, M., et al. 2024. Curr Med Chem.. PMID: 38213178
- Waldenström Macroglobulinemia-Associated Peripheral Neuropathy in the Brachial Plexus With Bing-Neel Syndrome Diagnosed Through Repeated Cerebrospinal Tests. | Hatasa, M., et al. 2024. Cureus. 16: e52400. PMID: 38361676
- Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. | Yonezawa, H., et al. 2024. Neurooncol Adv. 6: vdae037. PMID: 38690230
Inhibitor of:
Btk, CARD 12, CD79B, HACS1, Ig λ chain, Integrin αL, MLSN1, Shank 3, and TNF receptor superfamily (TNFRSF).Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tirabrutinib, 10 mg | sc-507435 | 10 mg | $138.00 |